Galera Therapeutics, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OQB
Galera Therapeutics reports Q1 2026 results, detailing a significant merger with Obsidian Therapeutics, a concurrent $350M PIPE financing, and substantial doubt about its ability to continue as a going concern.
OQB
Galera Therapeutics has completed a strategic pivot, selling its dismutase mimetics assets and focusing on a new breast cancer therapy, while securing additional funding.
OQB
Galera Therapeutics, Inc. has shifted its strategic focus to advanced breast cancer therapies following an acquisition, but faces substantial doubt about its ability to continue as a going concern.
OQB
10-Q: Galera Therapeutics Shifts Focus to Breast Cancer Treatment After Nova Pharmaceuticals Acquisition
Galera Therapeutics reports Q1 2025 results, highlighting a strategic shift towards breast cancer treatment following the acquisition of Nova Pharmaceuticals and ongoing efforts to secure additional funding.
OQB
10-Q: Galera Therapeutics Reports Q3 2024 Results, Faces Uncertain Future After Failed Dissolution Vote
Galera Therapeutics reported its Q3 2024 results, highlighting significant reductions in operating expenses and a net loss, while also facing an uncertain future after stockholders rejected the proposed plan of dissolution.
OQB
Galera Therapeutics plans to dissolve and liquidate the company after failing to find a viable strategic alternative, pending stockholder approval.
OQB
Galera Therapeutics reports a net loss of $4.38 million for the first quarter of 2024, as the company continues to evaluate strategic alternatives after halting clinical trials.